Ionis Pharmaceuticals Inc
(NAS:IONS)
$
33.46
-0.64 (-1.88%)
Market Cap: 5.28 Bil
Enterprise Value: 4.25 Bil
PE Ratio: 0
PB Ratio: 7.97
GF Score: 53/100 Ionis Pharmaceuticals Inc at TD Cowen RNA Therapeutics Summit (Virtual) Transcript
Jul 10, 2023 / 02:25PM GMT
Release Date Price:
$41.78
Yaron Benjamin Werber
TD Cowen, Research Division - MD & Senior Biotechnology Analyst
Well, good morning, everybody, and thank you for joining us for our 2nd RNA Summit. I'm Yaron Werber, on the biotech team here at TD Cowen, and it's a great pleasure to moderate the next session with Ionis Pharmaceuticals with Brett Monia, who is the Chief Executive Officer.
Brett, good morning. Right and early on your side. Thanks for joining us.
Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Good morning, Yaron. it's a pleasure to be here.
Questions & Answers
Yaron Benjamin Werber
TD Cowen, Research Division - MD & Senior Biotechnology Analyst
So lots to talk about. I want to kick off with eplontersen, especially on the heels of the 85 week data was literally which just got presented showing a nice sustainability now we've seen from 35 weeks to 66 weeks, and now to 85 weeks on TTR reduction and clinical outcomes as well. The PDUFA is coming up in December for TTR
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot